| A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma M Attal, JL Harousseau, AM Stoppa, JJ Sotto, JG Fuzibet, JF Rossi, ... New England Journal of Medicine 335 (2), 91-97, 1996 | 3594 | 1996 |
| Single versus double autologous stem-cell transplantation for multiple myeloma M Attal, JL Harousseau, T Facon, F Guilhot, C Doyen, JG Fuzibet, ... New England journal of medicine 349 (26), 2495-2502, 2003 | 1434 | 2003 |
| InterGroupe Francophone du Myelome M Attal, JL Harousseau, T Facon, F Guilhot, C Doyen, JG Fuzibet, ... N Engl J Med 349 (26), 2495-2502, 2003 | 1434* | 2003 |
| Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome H Avet-Loiseau, M Attal, P Moreau, C Charbonnel, F Garban, C Hulin, ... Blood 109 (8), 3489-3495, 2007 | 1258 | 2007 |
| Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6 B Klein, XG Zhang, M Jourdan, J Content, F Houssiau, L Aarden, ... | 1015 | 1989 |
| Genetics and cytogenetics of multiple myeloma: a workshop report R Fonseca, B Barlogie, R Bataille, C Bastard, PL Bergsagel, M Chesi, ... Cancer research 64 (4), 1546-1558, 2004 | 953 | 2004 |
| Interleukin-6 in human multiple myeloma B Klein, XG Zhang, ZY Lu, R Bataille Blood 85 (4), 863-872, 1995 | 737 | 1995 |
| Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell … P Moreau, T Facon, M Attal, C Hulin, M Michallet, F Maloisel, JJ Sotto, ... Blood, The Journal of the American Society of Hematology 99 (3), 731-735, 2002 | 729 | 2002 |
| Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. R Bataille, M Jourdan, XG Zhang, B Klein The Journal of clinical investigation 84 (6), 2008-2011, 1989 | 613 | 1989 |
| Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment N Giuliani, R Bataille, C Mancini, M Lazzaretti, S Barillé Blood, The Journal of the American Society of Hematology 98 (13), 3527-3533, 2001 | 586 | 2001 |
| Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells S Derenne, B Monia, NM Dean, JK Taylor, MJ Rapp, JL Harousseau, ... Blood, The Journal of the American Society of Hematology 100 (1), 194-199, 2002 | 554 | 2002 |
| Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical … H Avet-Loiseau, T Facon, B Grosbois, F Magrangeas, MJ Rapp, ... Blood, The Journal of the American Society of Hematology 99 (6), 2185-2191, 2002 | 494 | 2002 |
| Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody JT Beck, SM Hsu, J Wijdenes, R Bataille, B Klein, D Vesole, K Hayden, ... New England Journal of Medicine 330 (9), 602-605, 1994 | 462 | 1994 |
| C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system R Bataille, M Boccadoro, B Klein, B Durie, A Pileri | 448 | 1992 |
| Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high … T Facon, H Avet-Loiseau, G Guillerm, P Moreau, F Genevieve, ... Blood, The Journal of the American Society of Hematology 97 (6), 1566-1571, 2001 | 446 | 2001 |
| Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid … O Decaux, L Lodé, F Magrangeas, C Charbonnel, W Gouraud, ... Journal of Clinical Oncology 26 (29), 4798-4805, 2008 | 445 | 2008 |
| Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy P Moreau, T Facon, X Leleu, N Morineau, P Huyghe, JL Harousseau, ... Blood, The Journal of the American Society of Hematology 100 (5), 1579-1583, 2002 | 431 | 2002 |
| Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival S Wuilleme-Toumi, N Robillard, P Gomez, P Moreau, S Le Gouill, ... Leukemia 19 (7), 1248-1252, 2005 | 414 | 2005 |
| Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA–Italian Multiple Myeloma Network A Palumbo, P Falco, P Corradini, A Falcone, F Di Raimondo, N Giuliani, ... J Clin Oncol 25 (28), 4459-4465, 2007 | 381 | 2007 |
| Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma R Bataille, B Barlogie, ZY Lu, JF Rossi, T Lavabre-Bertrand, T Beck, ... | 377 | 1995 |
